Epigenomics Finally Gains FDA Approval For Epi proColon Blood Test
Executive Summary
Epigenomics has finally gained US FDA approval for its Epi proColon noninvasive colorectal cancer screening test, ending what has been a long, obstacle-filled journey for the German-US molecular diagnostics company.
You may also be interested in...
Exact Sciences Launches First Stool-Based DNA Screening Test For Colorectal Cancer
With the cost of treating colon cancer in the US projected to reach $20 billion annually by 2020, Exact Sciences hopes to improve colorectal cancer screening and survival rates with Cologuard, the first FDA-cleared noninvasive screening test that analyzes both DNA and blood biomarkers in stool.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.